Profitability Ratios
| Ratio |
Value |
| GP Margin |
-284.1% |
| EBIT Margin |
-11961.4% |
| EBITDA Margin |
-11722.7% |
| Operating Margin |
-11961.4% |
| Pretax Margin |
-15861.4% |
| Cont. Ops Margin |
-15861.4% |
| Net Margin |
-15861.4% |
| Bottom Line Margin |
-15861.4% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
0.53 |
| Quick Ratio |
0.53 |
| Solvency Ratio |
-0.883 |
| Cash Ratio |
0.15 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
-0.13
Peer avg not available.
|
| PEG Ratio |
0.01 |
| Forward PEG |
0.01 |
| Price/Book |
-0.19 |
| Price/Sales |
20.78 |
| Price/FCF |
-0.17 |
| Price/Op Cash Flow |
-0.17 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.8468 |
| Debt/Equity |
-0.5005 |
| Debt/Capital |
-1.0018 |
| Long-Term Debt/Capital |
-0.1047 |
| Financial Leverage |
-0.59 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
-0.02 |
| Operating Cash Flow Ratio |
-1.760 |
| Operating Cash Flow/Sales |
-12451.1% |
| Free Cash Flow/Operating Cash Flow |
100.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-2.24 |
| Interest Coverage |
-12.9631 |
| Short-Term Operating Cash Flow Coverage |
-2.88 |
| Operating Cash Flow Coverage |
-2.24 |
| Capital Expenditure Coverage |
0.00 |
| Dividend + Capital Expenditure Coverage |
0.00 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.05 |
| EPS |
-8.623 |
| Debt/Share |
3.5265 |
| Cash/Share |
0.61 |
| Book Value/Share |
-6.04 |
| Tangible BV/Share |
-7.07 |
| Equity/Share |
-6.04 |
| Operating Cash Flow/Share |
-6.769 |
| Capital Expenditure/Share |
0.000 |
| FCF/Share |
-6.769 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
1.326 |
| Price/Fair Value |
-0.19 |
| Debt/Market Cap |
2.5839 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-0.56 |
AIM - AIM ImmunoTech Inc.